Literature DB >> 2096409

Behavioural effects of the nicotinic agonists N-(3-pyridylmethyl)pyrrolidine and isoarecolone in rats.

C Reavill1, J A Waters, I P Stolerman, H S Garcha.   

Abstract

The nicotinic agonists N-(3-pyridylmethyl)pyrrolidine (PMP) and isoarecolone have been compared with (-)-nicotine in three behavioural procedures and as inhibitors of [3H]-(-)-nicotine binding. Locomotor activity was recorded as movements between beams of infra-red light (ambulation). In experimentally naive rats, nicotine, PMP and isoarecolone reduced ambulation. In rats receiving nicotine chronically and previously exposed to the activity cages, nicotine and PMP increased ambulation in a dose-related manner. However, isoarecolone did not increase ambulation at doses that were active in other procedures. In rats trained to discriminate nicotine from saline in a two-bar operant conditioning procedure with food reinforcement, there was full generalization to PMP. It was also found that PMP potently inhibited the binding of [3H]-(-)-nicotine to rat brain membranes in vitro. These results were discussed with previous data for the discriminative stimulus and ligand-binding effects of isoarecolone obtained under similar conditions. The relative potency of PMP in different behavioural procedures was similar to that of (-)-nicotine. However, isoarecolone was relatively 10 times more potent in decreasing ambulation than would have been expected from its potency in the ligand-binding and discriminative stimulus procedures. The results suggest that the pharmacodynamic action of isoarecolone differs from that of nicotine and PMP, and that it will be a useful probe in further analyses of central nicotinic mechanisms.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2096409     DOI: 10.1007/bf02247135

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  26 in total

1.  Studies on pyridine alkaloids and their analogues.

Authors:  F Haglid
Journal:  Acta Pharm Suec       Date:  1967-04

Review 2.  Primary cholinergic and indirect dopaminergic mediation of behavioural effects of nicotine.

Authors:  I P Stolerman; C Reavill
Journal:  Prog Brain Res       Date:  1989       Impact factor: 2.453

3.  Structural and electronic requirements for potent agonists at a nicotinic receptor.

Authors:  C E Spivak; T M Gund; R F Liang; J A Waters
Journal:  Eur J Pharmacol       Date:  1986-01-14       Impact factor: 4.432

4.  Purification and characterization of a nicotinic acetylcholine receptor from rat brain.

Authors:  P Whiting; J Lindstrom
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

5.  Acute and chronic tolerance to nicotine measured by activity in rats.

Authors:  I P Stolerman; R Fink; M E Jarvik
Journal:  Psychopharmacologia       Date:  1973-06-29

6.  Behavioural and pharmacokinetic studies on nicotine, cytisine and lobeline.

Authors:  C Reavill; B Walther; I P Stolerman; B Testa
Journal:  Neuropharmacology       Date:  1990-07       Impact factor: 5.250

7.  Isoarecolone can inhibit nicotine binding and produce nicotine-like discriminative stimulus effects in rats.

Authors:  C Reavill; C E Spivak; I P Stolerman; J A Waters
Journal:  Neuropharmacology       Date:  1987-07       Impact factor: 5.250

8.  Role of training dose in discrimination of nicotine and related compounds by rats.

Authors:  I P Stolerman; H S Garcha; J A Pratt; R Kumar
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

9.  The effects of nicotine on locomotor activity in non-tolerant and tolerant rats.

Authors:  P B Clarke; R Kumar
Journal:  Br J Pharmacol       Date:  1983-02       Impact factor: 8.739

10.  Exposure to nicotine enhances the behavioral stimulant effect of nicotine and increases binding of [3H]acetylcholine to nicotinic receptors.

Authors:  C Ksir; R Hakan; D P Hall; K J Kellar
Journal:  Neuropharmacology       Date:  1985-06       Impact factor: 5.250

View more
  9 in total

Review 1.  Neuropharmacology of the interoceptive stimulus properties of nicotine.

Authors:  Thomas E Wooters; Rick A Bevins; Michael T Bardo
Journal:  Curr Drug Abuse Rev       Date:  2009-09

2.  Mecamylamine but not the alpha7 receptor antagonist alpha-bungarotoxin blocks sensitization to the locomotor stimulant effects of nicotine.

Authors:  F E Kempsill; J A Pratt
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

3.  Release of [3H]-noradrenaline from rat hippocampal synaptosomes by nicotine: mediation by different nicotinic receptor subtypes from striatal [3H]-dopamine release.

Authors:  P B Clarke; M Reuben
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

4.  Locomotor activation and dopamine release produced by nicotine and isoarecolone in rats.

Authors:  P Whiteaker; H S Garcha; S Wonnacott; I P Stolerman
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

5.  Evidence of cross-tolerance between behavioural effects of nicotine and cocaine in mice.

Authors:  Rajeev I Desai; Philip Terry
Journal:  Psychopharmacology (Berl)       Date:  2003-01-24       Impact factor: 4.530

6.  Behavioural and ligand-binding studies in rats with 1-acetyl-4-methylpiperazine, a novel nicotinic agonist.

Authors:  H S Garcha; P Thomas; C E Spivak; S Wonnacott; I P Stolerman
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  The effects of varenicline on methamphetamine self-administration and drug-primed reinstatement in female rats.

Authors:  Steven T Pittenger; Scott T Barrett; Shinnyi Chou; Rick A Bevins
Journal:  Behav Brain Res       Date:  2015-11-27       Impact factor: 3.332

8.  Dissociations between the locomotor stimulant and depressant effects of nicotinic agonists in rats.

Authors:  I P Stolerman; H S Garcha; N R Mirza
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

9.  Acute and chronic nicotine effects on measures of activity in rats: a multivariate analysis.

Authors:  C Ksir
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.